WO2021088987A1 - 作为选择性her2抑制剂的盐型、晶型及其应用 - Google Patents
作为选择性her2抑制剂的盐型、晶型及其应用 Download PDFInfo
- Publication number
- WO2021088987A1 WO2021088987A1 PCT/CN2020/127123 CN2020127123W WO2021088987A1 WO 2021088987 A1 WO2021088987 A1 WO 2021088987A1 CN 2020127123 W CN2020127123 W CN 2020127123W WO 2021088987 A1 WO2021088987 A1 WO 2021088987A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- compound
- formula
- angles
- following
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 157
- 150000003839 salts Chemical group 0.000 title abstract description 6
- 229940125497 HER2 kinase inhibitor Drugs 0.000 title abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 121
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 116
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 11
- 238000001228 spectrum Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 description 32
- 239000000243 solution Substances 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 26
- 239000007787 solid Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 7
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 7
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 4
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- YRMOQCDUODUCRH-UHFFFAOYSA-N Cc1cc(Nc2ncn[n]3c2c(CN(CC2)CCC2N)cc3)ccc1Oc1cc2ncn[n]2cc1 Chemical compound Cc1cc(Nc2ncn[n]3c2c(CN(CC2)CCC2N)cc3)ccc1Oc1cc2ncn[n]2cc1 YRMOQCDUODUCRH-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950003463 tucatinib Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a salt form and its crystal forms as a HER2 inhibitor, and the application of the salt form and its crystal form in the preparation of medicines for treating HER2 related diseases.
- HER Human epidermal growth factor receptor
- EGFR Human epidermal growth factor receptor
- HER2 is overexpressed in a variety of cancers, and HER2 overexpression indicates that tumors are more aggressive and easier to relapse and metastasize early.
- Herceptin humanized anti-HER2 monoclonal antibody
- HER2 has become a therapeutic target for breast cancer, gastric cancer, and esophageal cancer.
- the HER2 small molecule kinase inhibitors currently on the market and under development usually also inhibit HER1 at the same time. Studies have shown that inhibiting HER1 will produce target-related side effects, such as skin rash and diarrhea.
- the present invention provides crystal form A of the compound of formula (I), and its X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 10.18 ⁇ 0.20°, 12.01 ⁇ 0.20° and 24.60 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 10.18 ⁇ 0.20°, 12.01 ⁇ 0.20°, 13.67 ⁇ 0.20°, 17.41 ⁇ 0.20°, 20.15 ⁇ 0.20 °, 20.59 ⁇ 0.20°, 22.64 ⁇ 0.20° and 24.60 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 5.80°, 10.18°, 12.01°, 13.67°, 14.70°, 16.32°, 17.41°, 18.86° , 19.73°, 20.15°, 20.59°, 21.61°, 22.64°, 23.57°, 24.13°, 24.60°, 25.41°, 25.77°, 28.52° and 29.15°.
- the XRPD pattern of the above-mentioned crystal form A is shown in FIG. 1.
- the XRPD pattern analysis data of the above-mentioned crystal form A is shown in Table 1.
- the present invention also provides the B crystal form of the compound of formula (I), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 6.41 ⁇ 0.20°, 12.86 ⁇ 0.20° and 15.64 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction peaks at the following 2 ⁇ angles: 6.41 ⁇ 0.20°, 7.32 ⁇ 0.20°, 12.86 ⁇ 0.20°, 15.64 ⁇ 0.20°, 16.26 ⁇ 0.20 °, 20.00 ⁇ 0.20°, 21.09 ⁇ 0.20° and 21.70 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction peaks at the following 2 ⁇ angles: 6.41°, 7.32°, 10.52°, 12.86°, 15.64°, 16.26°, 17.44°, 19.34° , 20.00, 21.09°, 21.70°, 22.48°, 25.84°, 27.40° and 28.72°.
- the XRPD pattern of the above-mentioned crystal form B is shown in FIG. 2.
- the XRPD pattern analysis data of the above-mentioned crystal form B is shown in Table 2.
- the differential scanning calorimetry curve of the above-mentioned crystal form B has an endothermic peak at 202.5 ⁇ 3°C.
- the DSC chart of the above-mentioned crystal form B is shown in FIG. 3.
- the present invention also provides crystal form C of the compound of formula (I), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 9.80 ⁇ 0.20°, 13.02 ⁇ 0.20° and 18.03 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form C has characteristic diffraction peaks at the following 2 ⁇ angles: 9.80 ⁇ 0.20°, 13.02 ⁇ 0.20°, 16.70 ⁇ 0.20°, 18.03 ⁇ 0.20°, 19.47 ⁇ 0.20 °, 21.00 ⁇ 0.20°, 23.67 ⁇ 0.20° and 25.15 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form C has characteristic diffraction peaks at the following 2 ⁇ angles: 9.80°, 13.02°, 16.70°, 18.03°, 19.47°, 21.00°, 22.74°, 23.67° And 25.15°.
- the XRPD pattern of the above-mentioned crystal form C is shown in FIG. 4.
- the XRPD pattern analysis data of the above-mentioned crystal form C is shown in Table 3.
- the differential scanning calorimetry curve of the above-mentioned crystal form C has an endothermic peak at 175.4 ⁇ 3°C.
- the DSC chart of the above-mentioned crystal form C is shown in FIG. 5.
- the present invention also provides the D crystal form of the compound of formula (I), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 12.64 ⁇ 0.20°, 21.38 ⁇ 0.20° and 22.02 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form D has characteristic diffraction peaks at the following 2 ⁇ angles: 12.64 ⁇ 0.20°, 14.32 ⁇ 0.20°, 15.78 ⁇ 0.20°, 18.40 ⁇ 0.20°, 20.20 ⁇ 0.20 °, 21.38 ⁇ 0.20°, 22.02 ⁇ 0.20° and 26.93 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form D has characteristic diffraction peaks at the following 2 ⁇ angles: 9.16°, 10.68°, 12.64°, 13.34°, 14.32°, 14.79°, 15.78°, 16.75° , 18.40°, 20.20°, 21.38°, 22.02°, 23.98°, 25.48°, 26.93° and 28.21°.
- the XRPD pattern of the above-mentioned crystal form D is shown in FIG. 6.
- the XRPD pattern analysis data of the above-mentioned crystal form D is shown in Table 4.
- the differential scanning calorimetry curve of the above-mentioned crystal form D has an endothermic peak starting point at 171.8 ⁇ 3°C.
- the DSC chart of the above-mentioned crystal form D is shown in FIG. 7.
- thermogravimetric analysis curve (TGA) of the above-mentioned crystal form D has a weight loss of 0.98% at 150 ⁇ 3°C.
- the TGA spectrum of the above-mentioned crystal form D is shown in FIG. 8.
- the present invention also provides a compound of formula (II):
- the present invention also provides the E crystal form of the compound of formula (II), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 19.76 ⁇ 0.20°, 22.83 ⁇ 0.20° and 25.59 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form E has characteristic diffraction peaks at the following 2 ⁇ angles: 10.26 ⁇ 0.20°, 11.49 ⁇ 0.20°, 13.25 ⁇ 0.20°, 13.95 ⁇ 0.20°, 15.41 ⁇ 0.20 °, 19.76 ⁇ 0.20°, 22.83 ⁇ 0.20° and 25.59 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form E has characteristic diffraction peaks at the following 2 ⁇ angles: 5.90°, 10.26°, 11.49°, 11.84°, 13.25°, 13.95°, 14.64°, 15.41° , 17.12°, 17.83°, 19.76°, 20.05°, 21.27°, 21.89°, 22.20°, 22.83°, 23.55°, 24.82°, 25.59°, 27.02°, 28.48°, 32.02° and 33.52°.
- the XRPD pattern of the above-mentioned crystal form E is shown in FIG. 9.
- the XRPD pattern analysis data of the above-mentioned crystal form E is shown in Table 5.
- the differential scanning calorimetry curve of the above-mentioned crystal form E has an onset of an endothermic peak at 215.0 ⁇ 3°C.
- the DSC chart of the above-mentioned crystal form E is shown in FIG. 10.
- the present invention also provides a compound of formula (III):
- the present invention also provides the F crystal form of the compound of formula (III), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 14.24 ⁇ 0.20°, 16.69 ⁇ 0.20° and 22.85 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form F has characteristic diffraction peaks at the following 2 ⁇ angles: 14.24 ⁇ 0.20°, 16.69 ⁇ 0.20°, 18.05 ⁇ 0.20°, 20.14 ⁇ 0.20°, and 22.85 ⁇ 0.20 °.
- the X-ray powder diffraction pattern of the above crystal form F has characteristic diffraction peaks at the following 2 ⁇ angles: 14.24°, 16.69°, 18.05°, 20.14° and 22.85°.
- the XRPD pattern of the above crystal form F is shown in FIG. 11.
- the XRPD pattern analysis data of the above-mentioned crystal form F is shown in Table 6.
- the present invention also provides a compound of formula (IV):
- the present invention also provides the G crystal form of the compound of formula (IV), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 11.47 ⁇ 0.20°, 16.88 ⁇ 0.20° and 23.78 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form G has characteristic diffraction peaks at the following 2 ⁇ angles: 11.47 ⁇ 0.20°, 14.50 ⁇ 0.20°, 15.48 ⁇ 0.20°, 16.29 ⁇ 0.20°, 16.88 ⁇ 0.20 °, 21.70 ⁇ 0.20°, 22.65 ⁇ 0.20° and 23.78 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form G has characteristic diffraction peaks at the following 2 ⁇ angles: 11.47°, 14.50°, 15.48°, 16.29°, 16.88°, 18.90°, 20.10°, 21.70° , 21.99°, 22.65°, 23.78°, 24.19° and 24.98°.
- the XRPD pattern of the above-mentioned crystal form G is shown in FIG. 12.
- the XRPD pattern analysis data of the above-mentioned crystal form G is shown in Table 7.
- the differential scanning calorimetry curve of the above-mentioned crystal form G has an endothermic peak at 215.0 ⁇ 3°C.
- the DSC chart of the above-mentioned crystal form G is shown in FIG. 13.
- the present invention also provides a compound of formula (V):
- the present invention also provides the H crystal form of the compound of formula (V), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 9.23 ⁇ 0.20°, 10.95 ⁇ 0.20° and 21.10 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form H has characteristic diffraction peaks at the following 2 ⁇ angles: 9.23 ⁇ 0.20°, 10.95 ⁇ 0.20°, 13.61 ⁇ 0.20°, 21.10 ⁇ 0.20°, 21.60 ⁇ 0.20 °, 22.59 ⁇ 0.20°, 23.79 ⁇ 0.20° and 24.98 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form H has characteristic diffraction peaks at the following 2 ⁇ angles: 9.23°, 10.95°, 12.95°, 13.61°, 15.37°, 16.08°, 16.97°, 17.98° , 19.28°, 19.95°, 21.10°, 21.60°, 22.59°, 23.79°, 24.98°, 26.54° and 32.64°.
- the crystal form of compound H of the above formula (V) has an XRPD pattern as shown in FIG. 14.
- the XRPD pattern analysis data of the above-mentioned compound H crystal form of formula (V) is shown in Table 8.
- the present invention also provides compounds of formula (VI):
- the present invention also provides the I crystal form of the compound of formula (VI), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 4.38 ⁇ 0.20°, 10.32 ⁇ 0.20° and 16.17 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form I has characteristic diffraction peaks at the following 2 ⁇ angles: 4.38 ⁇ 0.20°, 7.60 ⁇ 0.20°, 10.32 ⁇ 0.20°, 14.83 ⁇ 0.20°, 16.17 ⁇ 0.20 °, 20.13 ⁇ 0.20°, 23.45 ⁇ 0.20° and 24.99 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form I has characteristic diffraction peaks at the following 2 ⁇ angles: 4.38°, 4.97°, 6.13°, 7.60°, 10.32°, 11.85°, 12.88°, 14.30° , 14.83°, 16.17°, 17.48°, 18.63°, 19.81°, 20.13°, 21.86°, 22.62°, 23.45°, 24.99°, 25.75°, 27.66° and 29.88°.
- the XRPD pattern of the above-mentioned crystal form I is shown in FIG. 15.
- the XRPD pattern analysis data of the above-mentioned crystal form I are shown in Table 9.
- the present invention also provides the J crystal form of the compound of formula (VI), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 7.74 ⁇ 0.20°, 16.59 ⁇ 0.20° and 23.29 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form J has characteristic diffraction peaks at the following 2 ⁇ angles: 5.80 ⁇ 0.20°, 7.74 ⁇ 0.20°, 16.59 ⁇ 0.20°, 17.26 ⁇ 0.20°, 21.31 ⁇ 0.20 °, 22.82 ⁇ 0.20° and 23.29 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form J has characteristic diffraction peaks at the following 2 ⁇ angles: 5.80°, 7.74°, 11.56°, 13.29°, 13.88°, 14.73°, 15.51°, 16.59°, 17.26°, 18.37°, 18.87°, 20.13°, 21.31°, 21.58°, 22.35°, 22.82°, 23.29°, 24.56°, 24.95°, 26.09°, 26.68°, 27.94°, 31.23°, 33.36°, 34.90° , And 36.80°.
- the XRPD pattern of the above-mentioned crystal form J is shown in FIG. 16.
- the XRPD pattern analysis data of the above-mentioned crystal form J is shown in Table 10.
- the crystalline form of compound J of the above formula (VI) has a differential scanning calorimetry curve having an endothermic peak starting point at 189.8 ⁇ 3°C.
- the crystal form of compound J of the above formula (VI) has a DSC chart shown in FIG. 17.
- the present invention also provides a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), a compound of formula (V), a compound of formula (VI) and A, B, C, D, E , F, G, H, I and J crystal forms in the preparation of drugs for the treatment of HER2 related diseases.
- the salt form and each crystal form of the compound of the present invention are stable, are less affected by light, heat and humidity, have very high solubility, and have broad prospects for preparing medicines.
- the intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those skilled in the art.
- Well-known equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
- the solvent used in the present invention is commercially available.
- the present invention uses the following abbreviations: DCM stands for dichloromethane; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOH stands for ethanol; MeOH stands for methanol; TFA stands for trifluoroacetic acid; TsOH stands for P-toluenesulfonic acid; mp represents melting point; EtSO 3 H represents ethanesulfonic acid; MeSO 3 H represents methanesulfonic acid; ATP represents adenosine triphosphate; HEPES represents 4-hydroxyethylpiperazine ethanesulfonic acid; EGTA represents ethylene glycol bis(2 -Aminoethyl ether) tetraacetic acid; MgCl 2 stands for magnesium dichloride; MnCl 2 stands for manganese dichloride; DTT stands for dithiothreitol; DCC stands for dicycl
- Test method Approximately 10 mg sample is used for XRPD detection.
- Light tube voltage 45kV
- light tube current 40mA
- the first solar slit 0.04rad
- the second solar slit 0.04rad
- Test method Take a sample ( ⁇ 1-5mg) and place it in a DSC aluminum pan for testing. Under the condition of 50mL/min N 2 and at a heating rate of 10°C/min, heat the sample from 25°C (room temperature) to before the sample is decomposed .
- Figure 1 XRPD pattern of crystal form A.
- Figure 2 XRPD pattern of Form B.
- Figure 11 XRPD pattern of Form F.
- Figure 12 XRPD pattern of Form G.
- Figure 15 XRPD pattern of crystalline form I.
- the synthetic route is as follows:
- reaction solution was cooled to room temperature, slowly poured into 2.5L of water with stirring, filtered, the filter cake was washed with water (200mL*3), concentrated and dried under reduced pressure, the resulting crude product was mixed with petroleum ether (100mL) and ethyl acetate (100mL) as a mixed solvent
- the slurry was beaten twice, filtered, and the filter cake was rinsed with the same volume ratio of the above-mentioned mixed solvent (50 mL*3), and concentrated and dried under reduced pressure to obtain compound 10.
- reaction solution was cooled to room temperature, the precipitated solid was removed by filtration and the filter cake was rinsed with chlorobenzene (110 mL), the resulting filtrate was collected, and triethylamine (99.62g, 984.51mmol, 137mL, 1.65eq) was slowly added to it and the internal temperature was controlled Below 30°C, the reaction solution was stirred at 25°C for 16 hours. The reaction solution was directly concentrated to dryness under reduced pressure to obtain compound 12.
- the compound represented by formula (I) (56.5g) was added to a mixed solution of n-heptane and ethyl acetate (753mL:377mL), and the resulting suspension was heated and stirred at 50°C for 40 hours, slowly cooled, filtered, and solid After drying under reduced pressure, the crystal form D of the compound of formula (I) was obtained by XRPD detection.
- the influencing factors high temperature, high humidity and light
- the stability of acceleration conditions and the stability of intermediate conditions were investigated for the crystal form D.
- the purpose of this test is to detect the in vitro inhibitory activity of the compound against HER1 (ErbB1), HER2 (ErbB2), and HER4 (ErbB4).
- the enzymes used in this test are human ErbB1, ErbB2 and ErbB4.
- Eurofins Pharma Discovery Service provides an activity detection method.
- the results of the inhibitory activity of the test compounds against HER1, HER2, and HER4 are shown in Table 15.
- test compound buffer 5 ⁇ L
- peptide substrate poly(Glu, Tyr) 4:1) (2.5 ⁇ L)
- ErbB 4-20ng, 2.5 ⁇ L
- MnCl 2 50mM, 1.25 ⁇ L
- DH 2 O 3.75 ⁇ L
- [ ⁇ - 33 P]ATP 10 ⁇ L
- Luciferase in Cell-Titer-Glo reagent uses luciferin, oxygen and ATP as reaction substrates to produce oxyluciferin and release energy in the form of light. Since the luciferase reaction requires ATP, the total amount of light produced by the reaction is directly proportional to the total amount of ATP that reflects cell viability.
- NCI-N87 cell line ATCC-CRL-5822
- BT-474 cell line ATCC-HTB-20
- Cell culture medium (RPMI 1640 medium (Invitrogen#22400-105; 10% serum Invitrogen#10090148; L-glutamine 1 ⁇ , Gibco#25030-081; double antibody Hyclone#SV30010)
- the compound concentration is 10 mM, and the compound is diluted with DMSO to make the initial concentration 4 mM. Add compound to the plate, 9 ⁇ L per well.
- Test result The test result is shown in Table 16.
- the crystal form of compound D of formula (I) of the present invention has significant proliferation inhibitory activity on NCI-N87 cells and BT-474 cells.
- mice Female BALB/c nude mice, 6-8 weeks old, weighing 18-22 grams; Supplier: Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd.
- Human gastric cancer NCI-N87 cells were cultured in a monolayer in vitro.
- the culture conditions were RPMI-1640 medium with 10% fetal bovine serum, 100U/mL penicillin, 100 ⁇ g/mL streptomycin, 37°C, and 5% CO 2 culture.
- Tumor cell inoculation (tumor inoculation)
- test compound is formulated into a solution of appropriate concentration, and the solvent is 10% NMP+10% ethylene glycol stearate+80% water 4.
- the experimental index is to investigate whether the tumor growth is inhibited, delayed or cured.
- the tumor diameter was measured with vernier calipers twice a week.
- TGI (%) [1- (Average tumor volume at the end of a certain treatment group-the average tumor volume at the start of the treatment group) / (Average tumor volume at the end of the solvent control group- The average tumor volume at the start of treatment in the solvent control group)] ⁇ 100%.
- the statistical analysis is based on the RTV data at the end of the experiment using SPSS software for analysis.
- the comparison between two groups is analyzed by T test, and the comparison between three or more groups is analyzed by one-way ANOVA. If the variance is uniform (the F value is not significantly different), the analysis should be performed by Tukey's method. If the variance is not uniform ( There is a significant difference in the F value), and the Games-Howell method is used for testing. p ⁇ 0.05 considered a significant difference.
- the crystal form D of the compound of formula (I) of the present invention has an excellent effect of inhibiting tumor growth.
Abstract
Description
时间(min) | 流动相A(%) | 流动相B(%) |
0.0 | 95 | 5 |
8.0 | 20 | 70 |
9.0 | 30 | 70 |
9.1 | 95 | 5 |
10.0 | 95 | 5 |
化合物 | HER1IC 50(nM) | HER2IC 50(nM) | HER4IC 50(nM) |
式(I)化合物D晶型 | 582 | 4 | 167 |
Claims (46)
- 根据权利要求1所述的A晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:10.18±0.20°、12.01±0.20°、13.67±0.20°、17.41±0.20°、20.15±0.20°、20.59±0.20°、22.64±0.20°和24.60±0.20°。
- 根据权利要求2所述的A晶型,其XRPD图谱如附图1所示。
- 式(I)化合物的B晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:6.41±0.20°、12.86±0.20°和15.64±0.20°。
- 根据权利要求4所述的B晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:6.41±0.20°、7.32±0.20°、12.86±0.20°、15.64±0.20°、16.26±0.20°、20.00±0.20°、21.09±0.20°和21.70±0.20°。
- 根据权利要求5所述的B晶型,其XRPD图谱如附图2所示。
- 根据权利要求4~6任意一项所述的B晶型,其差示扫描量热曲线在202.5±3℃有一个吸热峰的起始点。
- 根据权利要求7所述的B晶型,其DSC图谱如附图3所示。
- 式(I)化合物的C晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:9.80±0.20°、13.02±0.20°和18.03±0.20°。
- 根据权利要求9所述的C晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:9.80±0.20°、13.02±0.20°、16.70±0.20°、18.03±0.20°、19.47±0.20°、21.00±0.20°、23.67±0.20°和25.15±0.20°。
- 根据权利要求10所述的C晶型,其XRPD图谱如附图4所示。
- 根据权利要求9~11任意一项所述的C晶型,其差示扫描量热曲线在175.4±3℃有一个吸热峰的起始点。
- 根据权利要求11所述的C晶型,其DSC图谱如附图5所示。
- 式(I)化合物的D晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:12.64±0.20°、21.38±0.20°和22.02±0.20°。
- 根据权利要求14所述的D晶型,其X射线粉末衍射图谱在下列2θ角处具有特征 衍射峰:12.64±0.20°、14.32±0.20°、15.78±0.20°、18.40±0.20°、20.20±0.20°、21.38±0.20°、22.02±0.20°和26.93±0.20°。
- 根据权利要求15所述的D晶型,X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:9.16°、10.68°、12.64°、13.34°、14.32°、14.79°、15.78°、16.75°、18.40°、20.20°、21.38°、22.02°、23.98°、25.48°、26.93°和28.21°。
- 根据权利要求16所述的D晶型,其XRPD图谱如附图6所示。
- 根据权利要求14~17任意一项所述的D晶型,其差示扫描量热曲线在171.8±3℃有一个吸热峰的起始点。
- 根据权利要求18所述的D晶型,其DSC图谱如附图7所示。
- 式(II)化合物的E晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:19.76±0.20°、22.83±0.20°和25.59±0.20°。
- 根据权利要求21所述E晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:10.26±0.20°、11.49±0.20°、13.25±0.20°、13.95±0.20°、15.41±0.20°、19.76±0.20°、22.83±0.20°和25.59±0.20°。
- 根据权利要求22所述的E晶型,其XRPD图谱如附图9所示。
- 根据权利要求21~23任意一项所述的E晶型,其差示扫描量热曲线在215.0±3℃有一个吸热峰的起始点。
- 根据权利要求24所述的E晶型,其DSC图谱如附图10所示。
- 式(III)化合物的F晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:14.24±0.20°、16.69±0.20°和22.85±0.20°。
- 根据权利要求27所述的F晶型,其X射线粉末衍射图谱在下列2θ角处具有特征 衍射峰:14.24±0.20°、16.69±0.20°、18.05±0.20°、20.14±0.20°和22.85±0.20°。
- 根据权利要求28所述的F晶型,其XRPD图谱如附图11所示。
- 式(IV)化合物的G晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:11.47±0.20°、16.88±0.20°和23.78±0.20°。
- 根据权利要求31所述的G晶型的X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:11.47±0.20°、14.50±0.20°、15.48±0.20°、16.29±0.20°、16.88±0.20°、21.70±0.20°、22.65±0.20°和23.78±0.20°。
- 根据权利要求32所述的G晶型,其XRPD图谱如附图12所示。
- 根据权利要求31~33所述的G晶型,其差示扫描量热曲线在215.0±3℃有一个吸热峰的起始点。
- 根据权利要求34所述的G晶型,其DSC图谱如附图13所示。
- 式(V)化合物的H晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:9.23±0.20°、10.95±0.20°和21.10±0.20°。
- 根据权利要求37所述的H晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:9.23±0.20°、10.95±0.20°、13.61±0.20°、21.10±0.20°、21.60±0.20°、22.59±0.20°、23.79±0.20°和24.98±0.20°。
- 根据权利要求38所述的H晶型,其XRPD图谱如附图14所示。
- 式(VI)化合物的I晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:4.38±0.20°、10.32±0.20°和16.17±0.20°。
- 根据权利要求41所述的I晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:4.38±0.20°、7.60±0.20°、10.32±0.20°、14.83±0.20°、16.17±0.20°、20.13±0.20°、23.45±0.20°和24.99±0.20°。
- 根据权利要求42所述的I晶型,其XRPD图谱如附图15所示。
- 式(VI)化合物的J晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.74±0.20°、16.59±0.20°和23.29±0.20°。
- 根据权利要求44所述的J晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.80±0.20°、7.74±0.20°、16.59±0.20°、17.26±0.20°、21.31±0.20°、22.82±0.20°和23.29±0.20°。
- 根据权利要求1~45所述的A、B、C、D、E、F、G、H、I或J晶型在制备治疗HER2相关疾病的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911087384 | 2019-11-08 | ||
CN201911087384.4 | 2019-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021088987A1 true WO2021088987A1 (zh) | 2021-05-14 |
Family
ID=75849784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/127123 WO2021088987A1 (zh) | 2019-11-08 | 2020-11-06 | 作为选择性her2抑制剂的盐型、晶型及其应用 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021088987A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024044570A1 (en) * | 2022-08-22 | 2024-02-29 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005065266A2 (en) * | 2003-12-29 | 2005-07-21 | Bristol-Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
CN1922182A (zh) * | 2003-12-29 | 2007-02-28 | 布里斯托尔-迈尔斯·斯奎布公司 | 作为激酶抑制剂的吡咯并三嗪化合物 |
WO2007059257A2 (en) * | 2005-11-15 | 2007-05-24 | Array Biopharma Inc. | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
CN101326171A (zh) * | 2005-11-16 | 2008-12-17 | Imtm股份有限公司 | 用作治疗炎症及其它疾病的前药的新型双用途肽酶抑制剂 |
CN101611041A (zh) * | 2006-12-12 | 2009-12-23 | 武田药品工业株式会社 | 稠合杂环化合物 |
WO2019214651A1 (zh) * | 2018-05-08 | 2019-11-14 | 南京明德新药研发有限公司 | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
-
2020
- 2020-11-06 WO PCT/CN2020/127123 patent/WO2021088987A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005065266A2 (en) * | 2003-12-29 | 2005-07-21 | Bristol-Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
CN1922182A (zh) * | 2003-12-29 | 2007-02-28 | 布里斯托尔-迈尔斯·斯奎布公司 | 作为激酶抑制剂的吡咯并三嗪化合物 |
WO2007059257A2 (en) * | 2005-11-15 | 2007-05-24 | Array Biopharma Inc. | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
CN101326171A (zh) * | 2005-11-16 | 2008-12-17 | Imtm股份有限公司 | 用作治疗炎症及其它疾病的前药的新型双用途肽酶抑制剂 |
CN101611041A (zh) * | 2006-12-12 | 2009-12-23 | 武田药品工业株式会社 | 稠合杂环化合物 |
WO2019214651A1 (zh) * | 2018-05-08 | 2019-11-14 | 南京明德新药研发有限公司 | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024044570A1 (en) * | 2022-08-22 | 2024-02-29 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3218366B1 (en) | Aurora a kinase inhibitor | |
US20200361908A1 (en) | Crystals of aniline pyrimidine compound serving as egfr inhibitor | |
KR20210029165A (ko) | 비아릴에테르형 퀴나졸린 유도체 | |
CN105980377A (zh) | 作为egfr-t790m激酶抑制剂的取代的嘧啶类化合物 | |
WO2019206336A1 (zh) | 一种***并嘧啶类化合物的晶型、盐型及其制备方法 | |
WO2021088987A1 (zh) | 作为选择性her2抑制剂的盐型、晶型及其应用 | |
WO2022052895A1 (zh) | 氮杂环丁烷取代化合物的晶型 | |
EA019183B1 (ru) | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина | |
WO2020253836A1 (zh) | 喹唑啉类化合物的晶型、盐型及其制备方法 | |
WO2020007219A1 (zh) | 一种egfr抑制剂的晶型及其制备方法 | |
WO2022257965A1 (zh) | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 | |
WO2020238802A1 (zh) | 一种c-MET/AXL抑制剂的晶型 | |
JP2019524857A (ja) | キナゾリン誘導体の塩の結晶 | |
CN111886228B (zh) | 一种c-MET/AXL抑制剂的晶型 | |
CA3098336C (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
WO2020224585A1 (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
WO2014111031A1 (zh) | 三嗪化合物、其药用盐、异构体或水合物及其药物组合物 | |
WO2023155841A1 (zh) | 嘧啶并环类化合物的盐型、晶型 | |
CN113784968B (zh) | Wee1抑制剂化合物的晶型及其应用 | |
WO2023169462A1 (zh) | 异色满类化合物的晶型 | |
Liu et al. | Synthesis and In Vitro Antitumor Activity Evaluation of Gefitinib-1, 2, 3-Triazole Derivatives | |
CN108299419B (zh) | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 | |
CN116685588A (zh) | 吡啶并吡咯类化合物的晶型、制备方法及其应用 | |
WO2019238088A1 (zh) | 吡啶并吡啶酮衍生物的盐型及晶型 | |
CN114539226A (zh) | 一种含吲哚类衍生物自由碱的晶型及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20884021 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20884021 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20884021 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14/11/2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20884021 Country of ref document: EP Kind code of ref document: A1 |